Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 10
Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL
An overview of challenges with CAR T-cell therapy, including combating T-cell exhaustion, the pros and cons of outpatient administration, logistical barriers, and the role of polatuzumab in bridging therapy, along with a discussion of non-cellular second-line options such as pola+BR and findings from L-MIND compared to real-world data
Video content above is prompted by the following:
Please give an overview of outstanding challenges for both patients and practitioners with the CAR T-cell regimen.
- How can T-cell exhaustion be combated?
- What are the advantages and limitations of outpatient administration. In your opinion, how can any issues with outpatient administration be addressed?
- What other logistical barriers are present with CAR T-cell regimens, and how does bridging therapy help address these concerns?
- What are your thoughts on the use of polatuzumab (pola) in bridging therapy (Liebers et al. Blood Adv 2021; Kim et al. ASH 2024)?
For a patient who does not receive 2L cellular therapy whether based on logistical or clinical reasons, what are the available treatment options?
- Please discuss key takeaways from pola+ BR (Sehn et al. Blood Adv. 2022). What can we learn from these updates?
- What are the major findings from L-MIND, and how does that compare to real world data (Duell J et al. Haematologica 2021; Zinzani et al. Clin Cancer Res 2021)?
- In your practice, how would you choose between the available options?